etranacogene dezaparvovec · Hemgenix

Gene therapy / editing

Approvedregulatory verdict

Evidence outlook

Approved: Hemophilia B

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also approved (1)
EU
  • Adults with severe and moderately severe hemophilia B without a history of Factor IX inhibitors (conditional marketing authorisation)
Product first approved 2023newsroom.csl.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Competitive landscape

This drug's own stage for Hemophilia B: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Etranacogene Dezaparvovec (Hemgenix): this drugApprovedGene therapy / editingFactor IX gene delivery (hFIX-Padua)not yet gradedNo reviewed efficacy summary in this indication
REGV131-LNP1265Phase 1/2Gene therapy / editingFactor IXnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Hemgenix (etranacogene dezaparvovec) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
October 2028 (1)
Phase 3Hemophilia BRecruiting
Est. primary completion 2028-10-04 · NCT06003387 · CT.gov ↗
What to watch

See the full readout calendar ↗